InnoCare announced that Dr. Xiangyang Chen was promoted to Chief Technology Officer (CTO)

On October 1st, 2019, InnoCare  announced that Dr. Xiangyang Chen, who has over 20 years’ experience in biomedical research, was promoted to CTO. He will continue to report directly to Dr. Jisong Cui, Chairman and CEO of InnoCare Pharma. Dr. Chen will continue to focus on the company’s technological development, especially in the development of drug screening technologies.

Dr. Chen joined InnoCare Pharma in October 2015. As one of the first major members to join the company, Dr. Chen played a key role in every important stage of the company’s development. His achievements include: establishing a “one-stop” R&D platform that laid a solid foundation for the company’s rapid growth; leading the establishment of the CMC platform which greatly expanded the company’s research and development capabilities; playing a major part in the creation and financing of Guangzhou InnoCare, which is set to be the company’s manufacturing base. Dr. Chen plays a critical role in the company’s R&D efforts, ensuring the safe and orderly development of the pre-clinical program.

Dr. Cui said “For many years, Xiangyang’s work performance at Innocare has been outstanding. His rigorous focus, dedication and proactive style deserves recognition. He is the embodiment of the company’s ideals and an exemplary model for all of InnoCare’s team. I look forward to working with him in the future.”

Dr. Chen brings more than 20 years of expertise in medicinal chemistry to InnoCare. Throughout this scientific career, Dr. Chen has 23 acquired patent applications and 17 peer-reviewed publications. He received his Bachelor of Science degree in applied chemistry from Peking University and went on the obtain his Doctor’s degree in organic chemistry from Emory University. He then served as a postdoctoral researcher in Biochemistry at the Albert Einstein College of Medicine. Dr. Chen became a principal scientist in the department of medicinal chemistry at Pfizer Inc. Afterwards he served as an executive director in the department of medicinal chemistry at Bioduro Inc.